Clinical Trial Update: Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination chemotherapy with rituximab in children with recurrent or refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Immunoblastic Large Cell Lymphoma
• Lymphoblastic Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma | Phase 2 | Status: TERMINATED